Delivery Order SPE2DR25D3201-SPE2DR26FT5FA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,507.70 to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of December 17, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,325.55 to AmerisourceBergen Drug Corp for LEQVIO 284 mg/1.5 ml syringes on June 26, 2025, with an ultimate completion date of July 18, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes valued at $24,507.70, with an ultimate completion date of November 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a $34,883.25 delivery order to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $27,906.60. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 ml syringes, with a contract value of $2,325.55 and an ultimate completion date of July 11, 2025. This is a firm fixed-price delivery order issued without a set-aside designation, reflecting a competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This award is a...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on June 18, 2025, by the Defense Logistics Agency (DLA) for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $16,278.85. This firm fixed-price delivery order, which is scheduled for completion by July 11, 2025, is unset-aside and competitively awarded. The award represents a continuation of the company's substantial role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $24,507.70 to AmerisourceBergen Drug Corp for LEQVIO 284 mg/1.5 mL syringes on December 3, 2025, with an ultimate completion date of December 24, 2025. This firm fixed-price delivery order is non-set-aside and represents a competitively awarded contract under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle that...
- The Defense Logistics Agency awarded a $46,511 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes, with an ultimate completion date of September 25, 2025. This competitively awarded contract contains no set-aside designation and specifies performance at AmerisourceBergen's location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $34,883.25. This non-set-aside, firm fixed-price delivery order is scheduled for completion by November 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. LEQVIO is a prescription pharmaceutical product used in cardiovascular treatment, reflecting the Defense Logistics Agency...
- SPE2DR25D3201Indefinite Delivery Contract
- SPE2DR25D3201-SPE2DR26FT5FADelivery Order
On January 8, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $24,812.70 to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes. This firm fixed-price delivery order, which is not set-aside, is expected to be completed by January 30, 2026, with performance taking place at the awardee's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. (which operates under the AmerisourceBergen brand name), is a major pharmaceutical distributor and critical federal vendor serving military and veteran healthcare systems. The company was competitively selected through the DLA's open procurement process and has demonstrated consistent capability in fulfilling federal medical supply needs across multiple therapeutic domains. This delivery order for LEQVIO, a specialty cardiovascular medication, exemplifies the company's role in supplying both brand-name and generic pharmaceuticals to support the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.8k | 1/7/26 |